Allogene Therapeutics, INC Form 4 insider transactions

Allogene Therapeutics CEO David Chang sold shares to cover tax withholding obligations related to vesting restricted stock units, as mandated by the company's equity incentive plan.

Allogene Therapeutics CFO Geoffrey M. Parker reports the purchase of 190 shares of common stock through a trust account, with subsequent restrictions placed to prevent future occurrences.